Johnson & Johnson (JNJ) Reports 69% Tumor Response Rate for Prostate Cancer Drug
Johnson & Johnson ($JNJ) has reported promising early results for its experimental prostate cancer pill, JNJ-6143, which has excited the oncology w...
Johnson & Johnson (JNJ)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Markel Gayner Asset Management Tom Gayner | 610,800 | $161,703,191 | 1.26% | |
| 2. | RWC Asset Management Tord Stallvik (Ceo) | 267,730 | $70,878,840 | +3% | 2.63% |
| 3. | Bailard Inc Thomas Bailard | 146,904 | $38,891,413 | -1% | 0.79% |
| 4. | Lee Munder Capital Group Lee Munder | 71,928 | $19,042,228 | -3% | 1.02% |
| 5. | Sivik Global Healthcare Krishen Sud | 24,000 | $6,353,760 | +20% | 3.63% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $206.15 | 1,250 | $257,687.50 | 1,849 | 2025-11-26 | Filing | |
| $145.53 | 100 | $14,553.00 | 250 | 2024-04-30 | Filing | |
| $147.22 | 1,000 | $147,220.00 | 1,000 | 2024-12-12 | Filing | |
| $127.69 | 500 | $63,843.00 | 16,030 | 2020-03-13 | Filing | |
| $141.28 | 5,000 | $706,399.00 | 5,000 | 2019-12-13 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $274.74 | 22,527 | $6,189,067.98 | 25,447 | 2026-09-02 | Filing | |
| $274.74 | 11,070 | $3,041,371.80 | 25,447 | 2026-09-02 | Filing | |
| $263.36 | 15,000 | $3,950,400.00 | 194,451 | 2026-08-17 | Filing | |
| $261.00 | 102,315 | $26,704,215.00 | 275,967 | 2026-08-13 | Filing | |
| $262.00 | 20,976 | $5,495,712.00 | 378,282 | 2026-08-13 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 6,491,294 | $1,718,505,190 | 3.78% | |
| 2. | 5,475,151 | $1,449,491,476 | 0.83% | |
| 3. | 3,182,317 | $842,486,603 | 0.72% | |
| 4. | 2,990,726 | $791,764,801 | 0.77% | |
| 5. | 2,906,056 | $770,977,741 | 1.96% |
News See All
Johnson & Johnson (JNJ) Drugs Lift Guidance, but Is 23 Times Earnings Fair?
Johnson & Johnson (NYSE:JNJ) raised its 2026 forecast earlier this month.
11 Best Cancer Stocks to Invest In Now
Cancer’s Burden Keeps the Search for Better Treatments Urgent For cancer patients, progress means more time, fewer side effects, and a better chance of recovery.
Johnson & Johnson (JNJ): Are Its Medical Device Deals Paying Off?
Johnson & Johnson (NYSE:JNJ) is turning acquired heart technologies into growing sales.
Johnson & Johnson (JNJ) Has Improved, but I’m Holding Off after the Rally
Johnson & Johnson’s ($JNJ) rally has me holding off, despite an improving business. The global healthcare products maker raised its full-year guida...
10 Best Big Name Stocks to Buy According to Financial Media
Wall Street has had a remarkable run in 2026, but the latest market turbulence is a reminder of how quickly investor sentiment can change.
Top 10 Unstoppable Dividend Stocks to Buy
Dividend cuts have been a major concern for income investors. It is easy to see why they dislike dividend reductions, suspensions, and eliminations.
Johnson & Johnson’s Dividend Machine Is Running. Can Earnings Keep Up?
Johnson & Johnson (NYSE:JNJ) stands out in the healthcare world for a reason.
Leaning Into Energy Stocks as Midterm Elections Draw Near
I don’t care to make predictions about elections. Even professional pollsters have difficulty with that task. I will predict that hostilities in t...
10 No-Brainer Stocks to Buy Now
Fed Chair Kevin Warsh gave no hint of another rate hike at an IMF event in Bangkok on October 16, and the odds of an October increase fell to roughly 15% on CME FedWatch, according to Benzinga on October...
Hedge Fund Resource Center